Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype

Research output: Contribution to journalReviewpeer-review

  1. Omics-based tracking of Pseudomonas aeruginosa persistence in "eradicated" cystic fibrosis patients.

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. COVID-19: guidance on palliative care from a European Respiratory Society international task force

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Morbidity and mortality in carriers of the cystic fibrosis mutation CFTR Phe508del in the general population

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The effect of exacerbation history on outcomes in the IMPACT trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Gerard N McElvaney
  • Robert A Sandhaus
  • Marc Miravitlles
  • Gerard M Turino
  • Niels Seersholm
  • Marion Wencker
  • Robert A Stockley
View graph of relations

α1-Antitrypsin deficiency (AATD), characterised by reduced levels or functionality of α1-antitrypsin (AAT), is a significantly underdiagnosed genetic condition that predisposes individuals to lung and liver disease. Most of the available data on AATD are based on the most common, severe deficiency genotype (PI*ZZ); therefore, treatment and monitoring requirements for individuals with the PI*SZ genotype, which is associated with a less severe AATD, are not as clear. Recent genetic data suggest the PI*SZ genotype may be significantly more prevalent than currently thought, due in part to less frequent identification in the clinic and less frequent reporting in registries. Intravenous AAT therapy, the only specific treatment for patients with AATD, has been shown to slow disease progression in PI*ZZ individuals; however, there is no specific evidence for AAT therapy in PI*SZ individuals, and it remains unclear whether AAT therapy should be considered in these patients. This narrative review evaluates the available data on the PI*SZ genotype, including genetic prevalence, the age of diagnosis and development of respiratory symptoms compared with PI*ZZ individuals, and the impact of factors such as index versus non-index identification and smoking history. In addition, the relevance of the putative 11 µM "protective threshold" for AAT therapy and the risk of liver disease in PI*SZ individuals is explored. The purpose of this review is to identify open research questions in this area, with the aim of optimising the future identification and management of PI*SZ individuals.

Original languageEnglish
JournalThe European respiratory journal
Issue number6
Publication statusPublished - Jun 2020

ID: 62429844